Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies

被引:6
作者
Puxeddu, Michela [1 ]
Shen, Hongliang [2 ]
Bai, Ruoli [3 ]
Coluccia, Antonio [1 ]
Nalli, Marianna [1 ]
Mazzoccoli, Carmela [4 ]
Da Pozzo, Eleonora [5 ]
Cavallini, Chiara [5 ]
Martini, Claudia [5 ]
Orlando, Viviana [6 ]
Biagioni, Stefano [6 ]
Mazzoni, Cristina [6 ]
Coluccia, Addolorata Maria Luce [7 ]
Hamel, Ernest [3 ]
Liu, Te [8 ]
Silvestri, Romano [1 ]
La Regina, Giuseppe [1 ]
机构
[1] Sapienza Univ Rome, Dept Drug Chem & Technol, Cenci Bolognetti Fdn, Inst Pasteur Italy, Piazzale Aldo Moro 5, I-00185 Rome, Italy
[2] Capital Med Univ, Beijing Friendship Hosp, Dept Urol, Beijing 100050, Peoples R China
[3] NCI, Screening Technol Branch, Dev Therapeut Program,NIH, Div Canc Treatment & Diag,Frederick Natl Lab Canc, Frederick, MD 21702 USA
[4] IRCCS, Ctr Riferimento Oncol Basilicata, Lab Ric Preclin & Traslaz, Via Padre Pio 1, I-83028 Rionero In Vulture, Italy
[5] Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy
[6] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Piazzale Aldo Moro 5, I-00185 Rome, Italy
[7] Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy
[8] Shanghai Univ Tradit Chinese Med, Shanghai Geriatr Inst Chinese Med, 365 South Xiangyang Rd, Shanghai 200031, Peoples R China
关键词
Tubulin; Leukemia; Solid tumor; Inhibitor; Pyrrole; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; AGENTS; IMATINIB; MICROTUBULES; RESISTANCE; APOPTOSIS; TUBULIN; GROWTH; SOLUBILITY;
D O I
10.1016/j.ejmech.2019.111828
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Novel 3-aroyl-1,4-diarylpyrrole derivatives were synthesized to explore structure-activity relationships at the phenyls at positions 1 and 4 of the pyrrole. The presence of amino phenyl rings at positions 1 and 4 of the pyrrole ring were found to be a crucial requirement for potent antitumor activity. Several compounds strongly inhibited tubulin assembly through binding to the colchicine site. Compounds 42, 44, 48, 62 and 69 showed antitumor activity with low nanomolar 1050 values in several cancer cell lines. Compound 48 was generally more effective as an inhibitor of glioblastoma, colorectal and urinary bladder cancer cell lines; 69 consistently inhibited CML cell lines and demonstrated superiority in nilotinib and imatinib resistant LAMA84-R and KBM5-T3151 cells. In animal models, compound 48 exhibited significant inhibition of the growth of T24 bladder carcinoma and ES-2 ovarian clear cell carcinoma tumors. Compounds 48 and 69 represent robust lead compounds for the design of new broadspectrum anticancer agents active in different types of solid and hematological tumors. (C) 2019 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:24
相关论文
共 47 条
  • [1] Tracking the ends: a dynamic protein network controls the fate of microtubule tips
    Akhmanova, Anna
    Steinmetz, Michel O.
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008, 9 (04) : 309 - 322
  • [2] [Anonymous], 2018, SCHRODINGER RELEASE
  • [3] [Anonymous], 2017, Schrodinger Release 2017-3, Schrodinger Suite 2017-3 Protein Preparation Wizard
  • [4] Epik, Schrodinger, LLC, New York, NY, USA
  • [5] Impact, Schrodinger, LLC, New York, NY, USA
  • [6] LigPrep, Schrodinger, LLC, New York, NY, USA
  • [7] Prime, Schrodinger, LLC, New York, NY, USA
  • [8] Chronic myeloid leukaemia
    Apperley, Jane F.
    [J]. LANCET, 2015, 385 (9976) : 1447 - 1459
  • [9] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE
    BEN-NERIAH, Y
    DALEY, GQ
    MESMASSON, AM
    WITTE, ON
    BALTIMORE, D
    [J]. SCIENCE, 1986, 233 (4760) : 212 - 214
  • [10] Blay J.Y., 2011, SEMIN ONCOL S1, V38, P53